Published in TB and Outbreaks Week, December 3rd, 2002
Herve Dega and colleagues at the Pitie-Salpetriere Faculty of Medicine in Paris examined amikacin's activity against Mycobacterium ulcerans, the pathogen that causes Buruli ulcer, when administered with rifampicin.
The combination of amikacin and rifampicin (RIF) was significantly more effective than other rifampicin-based regimens in animals, Dega and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.